Movement Alert｜Moderna, Inc. Rises 3.05% in Regular Trading, Cancer Vaccine Abstracts Accepted at ESMO With Phase 3 Full Data Due October 24

Market Focus09-24

On September 24, Moderna, Inc. rose 3.05% in regular trading, trading at 188.005 USD/share, with turnover of $737 million, extending its recent strong momentum.

On the news front, Moderna announced that three research abstracts for its personalized mRNA cancer vaccine intismeran autogene have been accepted by the European Society for Medical Oncology (ESMO) annual meeting. The most closely watched Phase 3 INTerpath-001 trial full melanoma data is scheduled for formal release on October 24, while the remaining two abstracts will disclose clinical data on the vaccine's application in pancreatic cancer and early-stage non-small cell lung cancer. The INTerpath-001 trial, co-developed with Merck, previously delivered positive Phase 3 results, achieving both recurrence-free survival and distant metastasis-free survival endpoints — marking the world's first mRNA cancer therapy validated in a randomized Phase 3 trial.

Separately, the options market saw a $9.18 million in-the-money CALL purchase targeting a November 20 expiry at a $160 strike price, with 2,000 contracts traded, reflecting concentrated bullish positioning on further upside. Multiple institutions have recently raised price targets, with Argus Research upgrading to Buy at $180 and Berenberg lifting its target to $100.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment